Oncolytics Biotech Shares Owned By Institutions vs. Book Value Per Share
| ONCY Stock | USD 0.93 0.02 2.11% |
For Oncolytics Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncolytics Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncolytics Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncolytics Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncolytics Biotech over time as well as its relative position and ranking within its peers.
Oncolytics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Return On Assets (0.71) | Return On Equity (1.38) |
The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oncolytics Biotech Book Value Per Share vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncolytics Biotech's current stock value. Our valuation model uses many indicators to compare Oncolytics Biotech value to that of its competitors to determine the firm's financial worth. Oncolytics Biotech is rated below average in shares owned by institutions category among its peers. It is rated below average in book value per share category among its peers creating about 0.21 of Book Value Per Share per Shares Owned By Institutions. The ratio of Shares Owned By Institutions to Book Value Per Share for Oncolytics Biotech is roughly 4.76 . At this time, Oncolytics Biotech's Book Value Per Share is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncolytics Biotech's earnings, one of the primary drivers of an investment's value.Oncolytics Book Value Per Share vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Oncolytics Biotech |
| = | 1.76 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Oncolytics Biotech |
| = | 0.37 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Oncolytics Book Value Per Share Comparison
Oncolytics Biotech is currently under evaluation in book value per share category among its peers.
Oncolytics Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncolytics Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncolytics Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Oncolytics Biotech's change in net profit over the period of time. It can combine multiple indicators of Oncolytics Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 544 K | 516.8 K | |
| Operating Income | -33.8 M | -32.1 M | |
| Net Loss | -27.8 M | -29.1 M | |
| Income Tax Expense | 97 K | 92.2 K | |
| Net Loss | -32.4 M | -30.7 M | |
| Income Before Tax | -27.7 M | -29 M | |
| Total Other Income Expense Net | 6.1 M | 6.4 M | |
| Net Loss | -22.4 M | -21.2 M | |
| Net Interest Income | 1.2 M | 1.2 M | |
| Interest Income | 1.2 M | 1.2 M | |
| Change To Netincome | 801.5 K | 1.1 M | |
| Net Loss | (0.41) | (0.43) | |
| Income Quality | 1.03 | 0.71 | |
| Net Income Per E B T | 1.00 | 0.81 |
Oncolytics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncolytics Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncolytics Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncolytics Biotech's important profitability drivers and their relationship over time.
Use Oncolytics Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.Oncolytics Biotech Pair Trading
Oncolytics Biotech Pair Trading Analysis
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncolytics Biotech position
In addition to having Oncolytics Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sports Thematic Idea Now
Sports
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.